Ebola

Johnson & Johnson earned the #2 spot on the Access to Medicine Index, an important measurement of the company’s longstanding commitment to make lifesaving medicine available and accessible to those who need it most.

For more than a century, Johnson & Johnson has used a core set of values to help build its business. Now, that sense of purpose has landed it on the Fortune ROL100, a new ranking of corporate leadership.

For Women’s History Month, we’re spotlighting three of the company’s pioneering early female scientists—and their modern-day counterparts, who are not only innovating in the lab, but also paving the way for the next generation of powerhouse women.

The Access to Medicine Index, a ranking of pharmaceutical companies’ work to distribute medications to low- and middle-income countries, just named Johnson & Johnson #3 on its biennial list, underscoring the company’s deep history of ensuring people in underserved communities receive the treatments they need.

A potential COVID-19 vaccine. Passionate efforts toward achieving racial and social justice. Smarter, more sustainable product packaging. These are just a few of the resolutions company change makers are aiming to bring to light this year—and they’re already hard at work on them.

When you’re the CFO of a company, you have a holistic view of how a pandemic can touch every aspect of a business, especially when it’s a healthcare company. So we posed inquiring mind questions to Joe Wolk about what the past eight months have been like for him at the financial helm of the company—via a Zoom interview.

From epidemic masks that the company introduced during the Spanish flu pandemic to work it’s doing today on an investigational COVID-19 vaccine, learn how the company has been at the forefront of safeguarding global public health for well over a century.

The company is proud to have made the list for the second year in a row. From its work on an Ebola vaccine—and an investigational COVID-19 vaccine—to collaboration taking place across its Johnson & Johnson Innovation centers, we take a look at the innovative spirit that permeates the company’s culture.

With its global Phase 3 clinical trial now fully enrolled with approximately 45,000 adult participants, we share the most up-to-date information about the single-dose investigational vaccine candidate.

The clinical trial has completed full immunizations of the company’s investigational HIV vaccine regimen. Learn what this means for the future of fighting the disease—and also for the creation of a potential vaccine for COVID-19.